Skip to main content

Table 1 Selected baseline and demographic characteristics (N = 32).

From: Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years

Characteristic Mean (SD)
Age (y) 71.8 (7.5)
Length of symptoms (mo)* 29.6 (18.3)
Baseline MMSE 21.3 (4.1)
Baseline GDS 3.7 (0.78)
  1. MMSE = Mini-Mental Status Examination; GDS = Geriatric Deterioration Scale.
  2. *Length of symptoms prior to enrollment in the double-blind study.